Silence Therapeutics shares are trading higher. The company presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran in polycythemia vera at the EHA 2026 Annual Congress.

Benzinga Newsdesk www.benzinga.com Positive 62.1%

Neg 0% Neu 0% Pos 62.1%

Comments

No comments yet. Be the first!